50 Big Debates in Gynecologic Oncology
50 Big Debates in Gynecologic Oncology
Editors:
Dennis S. Chi, Memorial Sloan-Kettering Cancer Center, New York
Nisha Lakhi, Richmond University Medical Center, Staten Island
Nicoletta Colombo, University of Milan-Bicocca
Nisha Lakhi, Richmond University Medical Center, Staten Island
Nicoletta Colombo, University of Milan-Bicocca
Lea A. Moukarzel, Oliver Zivanovic, Shannon Armbruster, Fidel A. Valea, Arwa Mohammad, Deepa Maheswari M. Narasimhulu, Sean C. Dowdy, Kathryn Miller, Dib Sassine, Yukio Sonoda, Thomas Boerner, Kara Long Roche, Steven A. Narod, Thomas C. Wright, Ibraheem O. Awowole, Olusegun O. Badejoko, Eseohi Ehimiaghe, Edward Tanner, Gordon J. S. Rustin, Ilaria Betella, Matteo Repetto, Raanan Alter, Ernst Lengyel, Rachel N. Grisham, David M. Gershenson, Jason D. Wright, Jonathan Ledermann, Sophia Wong, Annalisa Garbi, Eleonora Zaccarelli, Federica Tomao, John K. Chan, Daniel S. Kapp, Michelle Davis, Ursula Matulonis, Olga T. Filippova, William P. Tew, Sven Mahner, Anca Chelariu-Raicu, Fabian Trillsch, Sean Kehoe, Jason Yap, Juliet E. Wolford, Robert E. Bristow, Beverly Long, William A. Cliby, Annalisa Garbi, Vanna Zanagnolo, Javier F. Magrina, Kristina Butler, Paul Magtibay, S. Lot Aronson, Gabe S. Sonke, Willemien J. van Driel, Richard Schwameis, Luis M. Chiva, Philipp Harter, Molly Morton, Tiffany Sia, Laura M. Chambers, Roberto Vargas, Robert Debernardo, Angeles Alvarez Secord, Laura J. Havrilesky, Antonio González-Martín, Hélène Vanacker, Olivia Le Saux, Isabella Ray-Coquard, Duaa H. Al-Rawi, Karen Cadoo, Roisin O'Cearbhaill, Alvin Jun Xing Lee, Jonathan A. Ledermann, Krishnansu S. Tewari, Francisco Grau, Lorena Fariñas-Madrid, Ana Oaknin, David F. Cantú de León, Daniel Flores Alatriste, Milagros Pérez Quintanilla, Olivia Lara, Bhavana Pothuri, Sarah Ehmann, Andreas du Bois, Mareike Bommert, Anca Chelariu-Raicu, Robert Coleman, Karin K. Shih, Claire F. Friedman, Tiffany Y. Sia, Dmitriy Zamarin, Joanie M. Hope, Jill S. Whyte, Claire V. Hoppenot, S. Diane Yamada, Michael J. Seckl, Michael L. Friedlander, Olivia Le Saux, Hélène Vanacker, Isabella Ray-Coquard, Dib Sassine, Chrissy Liu, Jubilee Brown, Giorgia Mangili, Alice Bergamini, Luca Bocciolone, Amanika Kumar, Simrit Warring, Daniel Margul, Thomas J. Herzog, Eric Pujade-Lauraine, Benoit You, Jean Sebastien Frenel, Kutluk Oktay, Enes Taylan, Jessica E. Parker, David S. Miller, Amanda N. Fader, Payam Katebi Kashi, Camilla Yu, Michael Wilkinson, Paul Downey, Donal J. Brennan, Daniela Matei, Stephanie M. de Boer, Catheryn M. Yashar, Ryan M. Kahn, Ginger J. Gardner, Alessia Aloisi, Federica Tomao, Eleonora Zaccarelli, Lauren Thomaier Bollinger, Melissa A. Geller, Nasuh Utku Dogan, Selen Dogan, Brooke M. Lamparello, Joyce N. Barlin, Frederick M. Howard, Gini F. Fleming, Lea A. Moukarzel, Kevin Espino, Chris Awtrey, Marcela Del Carmen, Pamela T. Soliman, Roni Nitecki, Julianne Lima, Susana Banerjee, Ana Oaknin, Lorena Farinas-Madrid, J. Francisco Grau, William A. Zammarrelli III, Vicky Makker, Domenica Lorusso, Sara Bouberhan, Whitfield B. Growdon, Richard T. Penson, Anastasios Tranoulis, Kavita Singh, Janos Balega, Melissa Frey, Ryan Kahn, Sumer K. Wallace, Jamie N. Bakkum-Gamez, Beatrice Seddon, Giovanni Aletti, Félix Blanc-Durand, Amandine Maulard, Patricia Pautier, Vanna Zanagnolo, Francesco Multinu, Stefano Bogliolo, Pedro T. Ramirez, Joo-Hyun Nam, Jeong-Yeol Park, Zibi Marchocki, Allan Covens, Michael Frumovitz, Marie Plante, Dib Sassine, Alexandra Diggs, Philippe Morice, Sebastien Gouy, Cyrus Chargari, Jolien Haesen, Rawand Salihi, Ignace B. Vergote, Sudeep Gupta, Amita Maheshwari, Supriya Chopra, Chrisann Kyi, Fernando Cotait Maluf, Daniele Xavier Assad, Angelica Nogueira-Rodrigues, Lilian Given, Ryan M. Kahn, Wui-Jin Koh, Sabrina M. Bedell, Britt K. Erickson, Rachel C. Sisodia, Aaron M. Praiss, Kaled M. Alektiar, John P. Geisler, Kelly J. Manahan, Mario M. Leitao
View all contributors
Published:
July 2023
Availability:
This ISBN is for an eBook version which is distributed on our behalf by a third party.
Format:
Adobe eBook Reader
ISBN:
9781108936453
Looking for an examination copy?
If you are interested in the title for your course we can consider offering an examination copy. To register your interest please contact [email protected] providing details of the course you are teaching.
$44.99
USDAdobe eBook Reader
$44.99
USD
Paperback
Highlighting over 50 hot topics where controversy exist in management of patients with gynecologic malignancy, this book presents expertly argued opinions for and against, incorporating current evidence and clinical trials outcomes. A diverse range of topics are included that pertain to several disciplines in gynecologic oncology, including surgical management of disease, medical oncology, immunotherapy, radiation therapy, as well as screening, preventive and palliative care. This book will be relevant to a diverse audience of practitioners and trainees including gynecologists, gynecological oncologists, surgeons, medical oncologists, radiation oncologists, and general medics. It will be a useful guide for practicing clinicians managing their patients, as well as a concise textbook for trainees and students preparing for examinations and board certifications in gynecologic oncology. Readers will gain an insight into topical controversies, critically evaluating the different sides to enhance their own clinical practice.
- Debates are being increasingly used as teaching tools, helping readers to engage and critically evaluate the topic
- Incorporates topics pertaining to several disciplines in gynaecologic oncology, including surgical management of disease, medical oncology, immunotherapy, radiation therapy, as well as preventive and palliative care, appealing to a wide audience of clinicians and trainees such as gynecologists, gynecological oncologists, surgeons, medical oncologists, radiation oncologists, and general medics
- Authors are authorities in the field, combining years of experience with fresh and innovative ideas and opinions to advance the specialty and incorporating global inter-disciplinary and multi-disciplinary perspectives on best management
Product details
July 2023Adobe eBook Reader
9781108936453
0 pages
This ISBN is for an eBook version which is distributed on our behalf by a third party.
Table of Contents
- Section I: Perioperative Management
- 1A. Should routine mechanical bowel preparation be performed before primary debulking surgery? Yes Lea A. Moukarzel and Oliver Zivanovic
- 1B. Should routine mechanical bowel preparation be performed before primary debulking surgery? No Shannon Armbruster and Fidel A. Valea
- 2A . Should preoperative carbohydrate loading be routine prior to debulking surgery? Yes Arwa Mohammad, Deepa Maheswari M. Narasimhulu and Sean C. Dowdy
- 2B. Should preoperative carbohydrate loading be routine prior to debulking surgery? No Kathryn Miller, Dib Sassine and Yukio Sonoda
- Section II: Screening, Prevention and Early Diagnosis
- 3A. Should women with BRCA mutations be offered bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction? Yes Thomas Boerner and Kara Long Roche
- 3B. Should women with BRCA mutations be offered bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction? No Steven A. Narod
- 4A. Can high-risk HPV testing be used alone as the primary screening modality for cervical cancer? Yes Thomas C. Wright
- 4B. Can high-risk HPV testing be used alone as the primary screening modality for cervical cancer? No Ibraheem O. Awowole and Olusegun O. Badejoko
- Section III: Ovarian Cancer
- 5A. Should CA-125 surveillance be performed after completion of primary treatment for ovarian cancer patients in remission? Yes Eseohi Ehimiaghe and Edward Tanner
- 5B. Should CA-125 surveillance be performed after completion of primary treatment for ovarian cancer patients in remission? No Gordon J. S. Rustin
- 6A. In patients with BRCA-negative and HRD-negative epithelial ovarian cancer, should molecular profiling be routinely done to guide adjuvant therapy? Yes Ilaria Betella and Matteo Repetto
- 6B. In patients with BRCA-negative and HRD-negative epithelial ovarian cancer, should molecular profiling be routinely done to guide adjuvant therapy? No Raanan Alter and Ernst Lengyel
- 7A. Is MEK Inhibitor Therapy the Best Treatment Recommendation for Low-Grade Serous Ovarian Cancer Patients at First Relapse? Yes Rachel N. Grisham
- 7B. Is MEK Inhibitor Therapy the Best Treatment Recommendation for Low-Grade Serous Ovarian Cancer Patients at First Relapse? No David M. Gershenson
- 8A. Should Stage IC mucinous ovarian carcinoma be managed by observation or adjuvant chemotherapy? Observation Jason D. Wright
- 8B. Should Stage IC mucinous ovarian carcinoma be managed by observation or adjuvant chemotherapy? Adjuvant chemotherapy Jonathan Ledermann and Sophia Wong
- 9A. How many cycles of adjuvant chemotherapy should be administered to patients with high-risk Stage I epithelial ovarian cancer? Three cycles Annalisa Garbi, Eleonora Zaccarelli and Federica Tomao
- 9B. How many cycles of adjuvant chemotherapy should be administered to patients with high-risk Stage I epithelial ovarian cancer? Six cycles John K. Chan and Daniel S. Kapp
- 10A. Patients with advanced ovarian cancer who are 75 years old and older should routinely be treated withneoadjuvant chemotherapy: Yes Michelle Davis and Ursula Matulonis
- 10B. Patients with advanced ovarian cancer who are 75 years old and older should routinely be treated with neoadjuvant chemotherapy: No Olga T. Filippova and William P. Tew
- 11A. Should an attempt at aggressive cytoreduction be made for all surgical candidates with advanced ovarian cancer prior to treatment with adjuvant chemotherapy? Yes Sven Mahner, Anca Chelariu-Raicu and Fabian Trillsch
- 11B. Should an attempt at aggressive cytoreduction be made for all surgical candidates with advanced ovarian cancer prior to treatment with adjuvant chemotherapy? No Sean Kehoe and Jason Yap
- 12A. Should minimally invasive modalities be routinely/uniformly utilized for assessment of resectability prior to attempted primary debulking in patients with advanced ovarian cancer? Yes Juliet E. Wolford
